Solventum (NYSE: SOLV) announced on August 5 that it intends to separate its Health Information Systems (HIS) business, the healthcare-software unit that handles medical coding, revenue-cycle management, and clinician-productivity software for hospitals and health systems. The company has not committed to a specific structure yet: it says it will evaluate options including a spinoff into an independent public company, a combination with another established player in the space, or another type of transaction, with a decision driven by whichever path management believes maximizes shareholder value.

An Intention to Explore, Not a Signed Deal

This is an announced intention to explore separation, not a signed deal. Solventum’s own release states plainly that no decision has been made on the ultimate structure or timing, that there is no assurance a separation will happen at all, and that any transaction that does move forward would still need board approval, regulatory clearance, and other customary conditions. Investors should read this as the start of a process Solventum expects to take 12 to 18 months, not a completed transaction.

The Business Being Separated

Health Information Systems is a real business with scale, not just a division on paper. According to the release, it generated $1.4 billion in net sales for the twelve months ended December 31, 2025, with software deployed in more than 30 countries and used by over 75 percent of U.S. hospitals, built on more than four decades of medical coding expertise and processing roughly 660 million clinical documents a month. In plain terms, medical coding software translates a patient’s clinical record into the standardized billing codes that hospitals submit to insurers and government payers, and revenue-cycle management covers the broader process of tracking that billing from a patient’s visit through final payment; Solventum says its platform increasingly automates parts of that coding process rather than relying only on human coders. Solventum describes the segment’s addressable market at roughly $10 billion, growing an estimated 5 to 6 percent annually; that figure is the company’s own market estimate, not an independently verified number, and should be read that way.

Part of a Larger Pattern

This is not Solventum’s first major portfolio move since becoming an independent public company. Solventum was spun off from 3M in April 2024, and in February 2025 it agreed to sell its Purification and Filtration business to Thermo Fisher Scientific for $4.1 billion, a deal that closed in September 2025 for $4.0 billion in cash before adjustments, with proceeds used primarily to pay down debt. Solventum has publicly described that sale as part of a three-phase transformation plan, and this Health Information Systems separation is being framed the same way, as the next phase of narrowing the company to its MedSurg and Dental Solutions businesses.

What the Company Is Saying

CEO Bryan Hanson said the company has moved with urgency on portfolio optimization and described Health Information Systems as a differentiated business with a strong position and significant potential, framing separation as a way to let both resulting businesses pursue distinct growth agendas. That is a characterization from the company and its board, not an independently verified assessment of the businesses’ prospects.

Stated Rationale and What’s Missing

Solventum lists several reasons it believes separation could help both sides: sharper strategic focus for the remaining MedSurg and Dental Solutions businesses, a dedicated management team for Health Information Systems with control over its own capital allocation, and the flexibility for Health Information Systems to expand its autonomous medical-coding technology, enter international markets, and pursue partnerships or acquisitions on its own. Again, these are stated goals rather than guaranteed outcomes, and the release does not disclose a valuation range or estimated proceeds for Health Information Systems the way the Purification and Filtration sale disclosed a specific price.

Advisors and Timing

Morgan Stanley and Goldman Sachs are serving as financial advisors to Solventum on the process, with Cleary Gottlieb Steen & Hamilton as legal counsel, the same law firm that worked on the Thermo Fisher transaction. Solventum also released its second-quarter 2026 earnings the same day and held a joint investor call covering both the quarterly results and the proposed separation, which is typical practice for a major strategic announcement timed to a scheduled earnings date.

Broader Industry Context

Healthcare revenue-cycle and coding software has drawn steady acquisition interest across the broader healthcare IT sector in recent years, as hospitals look to reduce administrative costs and automate paperwork-heavy processes, which may help explain why Solventum is considering a combination with another established player as one possible path rather than only a standalone spinoff. The release does not name any potential combination partner, and none is speculated here.

What’s Next

For investors, the practical takeaway is that Solventum is continuing a pattern of shedding non-core segments to concentrate on fewer, larger businesses, following the same three-phase transformation logic that produced last year’s Purification and Filtration sale. Unlike that transaction, this one has no signed agreement, no disclosed price, and no certainty of outcome yet; Solventum has committed only to running a process over the next 12 to 18 months and providing updates as it progresses. This article covers a corporate strategy announcement and is not an investment recommendation.

Sources

• Solventum Announces Intent to Separate its Health Information Systems Business, PRNewswire, August 5, 2026.
• Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc., PRNewswire, September 2, 2025, cited for background on Solventum’s prior divestiture.

Editorial Disclosure

This article is based on a press release issued by Solventum on August 5, 2026, distributed via PRNewswire, with background context drawn from Solventum’s September 2025 announcement regarding its Purification and Filtration business, cited above. Solventum trades on the New York Stock Exchange under the ticker SOLV. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the structure, timing, or anticipated benefits of the proposed separation are forward-looking; Solventum has stated that no decision on structure or timing has been made and that there is no assurance a separation will occur. This article is for informational and educational purposes only and does not constitute investment advice. See our full DISCLAIMER.